Pfizer, Inc. (PFE) Monthly Report
Publication Date: September 22, 2024
Company Overview
Pfizer, Inc. (PFE), headquartered in New York City, is a prominent global biopharmaceutical company founded in 1849. Specializing in the healthcare sector, particularly within the drug manufacturing industry, Pfizer is committed to discovering, developing, manufacturing, and marketing a diverse range of health products. The company is recognized for its innovative treatments, particularly for cardiovascular and infectious diseases, including its well-known COVID-19 products, Comirnaty and Paxlovid. Strategic collaborations with biotechnology firms bolster Pfizer’s efforts to address unmet medical needs globally, underscoring its reputation as a leader in biopharmaceutical innovation.
Investment Opportunity
Pfizer presents a compelling investment opportunity, driven by its impressive total revenue of approximately $55.17 billion. With a current stock price of $29.42, there is substantial potential upside, as analysts project a target high price of $45.00, alongside a target mean price of $33.38. This optimistic outlook is supported by a favorable recommendation to buy, reflecting a consensus among 22 analysts that underscores confidence in the stock’s growth potential. Notably, Pfizer has a relatively low short interest of about 0.0115%, indicating strong market confidence in the company’s future performance.
Market Performance Analysis
Pfizer’s current stock price is performing slightly above its fifty-day average of $29.36, indicating stability. The stock has experienced notable fluctuations over the past year, with a fifty-two-week high of $34.11 and a low of $25.20. This dynamic price action suggests ongoing market interest and may present advantageous entry points for potential investors. With the analysts’ rating averaging at 2.4, there is consistent optimism regarding the stock’s potential for appreciation within a range defined by a target high of $45.00 and a target low of $27.00.
In conclusion, Pfizer, Inc.’s robust revenue, positive analyst sentiment, and dynamic price range establish it as an attractive investment within the pharmaceutical sector. Investors should closely monitor developments to leverage the anticipated growth in this evolving market landscape.
| Metric | Value |
|---|---|
| Market Cap | $166.7b |
| Total Debt | $69.9b |
| Total Cash | $7.1b |
| Shares Outstanding | 5.7b |
| Float Shares | 5.7b |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.